ClinicalTrials.gg

Breast Neoplasms clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 14,840 studies for Breast Neoplasms across more than 10 countries. 3,319 are recruiting or about to start. 12,540 of them are mainly about Breast Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 9 narrower conditions too, such as Triple Negative Breast Neoplasms: 15,814 studies, 3,664 open.

ClinicalTrials.gov finds 17,013 studies for Breast Neoplasms. How that becomes 14,832 here

This page counts the studies the registry files under Breast Neoplasms, and those it files under no condition that list Breast Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 17,013Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −973Filed under a narrower condition, counted on its own pageTriple Negative Breast Neoplasms 732 · Carcinoma, Intraductal, Noninfiltrating 87 · Hereditary Breast and Ovarian Cancer Syndrome 39 · Breast Carcinoma In Situ 27 · Inflammatory Breast Neoplasms 22 · Carcinoma, Lobular 22 · 3 more
  3. −397List Breast Neoplasms as a condition, but the registry did not file them under itMost often written as “Breast Cancer Female” (54), “Breast Cancer Lymphedema” (25), and “Anatomic Stage III Breast Cancer AJCC v8” (20). The registry filed them under other conditions only, most often Breast Cancer Lymphedema (63) and Neoplasms (29).
  4. −811Match it another way570 name it in the title, 49 in a keyword, and 192 by a synonym or other text the search reads.
  5. 14,832The count on this page1,285 of them list Breast Neoplasms in their own words; the registry filed them under no condition.

Status

Completed
6,995
Recruiting
2,398
Status unknown
1,613
Terminated
1,247
Active, not recruiting
1,124
Not yet recruiting
810

Phase

Phase 2
3,986
Phase 1
2,031
Phase 3
1,418
Phase 4
306
Early Phase 1
196

Where

United States
6,166
China
1,930
France
1,208
Canada
906
Spain
905
Italy
887

Who develops what

Add Breast Neoplasms to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 191 programs from 115 companies, 138 with this as their studies’ main aim; 53 with a live phase 3 study; 64 primary completions in the next 12 months. Compare Novartis, CSPC Pharmaceutical Group and Sino Biopharmaceutical here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
FulvestrantRecent, repeated
Evidence
  • NCT07861932 · KymaThera, Inc. · Phase 2 · live · background · “Fulvestrant” · registered Sep 2026
  • NCT07811232 · Advenchen Pharmaceuticals, LLC. · Phase 2 · live · background · “Fulvestrant” · registered Aug 2026
  • NCT07748208 · Hoffmann-La Roche · Phase 2 · live · background · “Fulvestrant” · registered Jul 2026
  • NCT07679269 · Novartis · Phase 2 · live · background · “Fulvestrant” · registered Jun 2026
  • NCT07570966 · Novartis · Phase 2 · background · “Fulvestrant” · registered Apr 2026
AstraZeneca70% of its industry studiesUS: off-patent, 11 generics marketedEU: off-patent, 1 generic authorized3050 studies
CapecitabineRecent, repeated
Evidence
  • NCT07824869 · Fosun Pharma · Phase 2 · live · background · “Capecitabine” · registered Sep 2026
  • NCT07684456 · Beijing Biostar Pharmaceuticals Co., Ltd. · Phase 3 · live · background · “Capecitabine” · registered Jun 2026
  • NCT07648914 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Capecitabine” · registered Jun 2026
  • NCT07461454 · MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3 · live · comparator · “Capecitabine” · registered Mar 2026
  • NCT07060807 · Merck & Co., Inc · Phase 3 · live · comparator · “Capecitabine” · registered Jul 2025
Hoffmann-La Roche33% of its industry studiesEU: off-patent, 4 generics authorized2130 studies
TrastuzumabRecent, repeated
Evidence
  • NCT07824869 · Fosun Pharma · Phase 2 · live · background · “Trastuzumab” · registered Sep 2026
  • NCT07683754 · Daiichi Sankyo · Phase 3 · live · background · “Trastuzumab” · registered Jun 2026
  • NCT07679269 · Novartis · Phase 2 · live · background · “Trastuzumab” · registered Jun 2026
  • NCT07545044 · CSPC Pharmaceutical Group Limited · Phase 2 · live · comparator · “Trastuzumab” · registered Apr 2026
  • NCT07518173 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Trastuzumab” · registered Apr 2026
Hoffmann-La Roche55% of its industry studiesUS: Hoffmann-La Roche (FDA 1998) + 6 othersEU: Hoffmann-La Roche (EMA 2000) + 8 others1930 studies
PaclitaxelRecent, repeated
Evidence
  • NCT07824869 · Fosun Pharma · Phase 2 · live · background · “Paclitaxel” · registered Sep 2026
  • NCT07648914 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Paclitaxel” · registered Jun 2026
  • NCT07377643 · Innovent Biologics, Inc. · Phase 3 · live · comparator · “Paclitaxel” · registered Jan 2026
  • NCT07060807 · Merck & Co., Inc · Phase 3 · live · comparator · “Paclitaxel” · registered Jul 2025
  • NCT07071337 · Sichuan Kelun Pharmaceutical Co.,Ltd. · Phase 3 · live · comparator · “Paclitaxel” · registered Jun 2025
Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed1724 studies
DocetaxelRecent, repeated
Evidence
  • NCT07824869 · Fosun Pharma · Phase 2 · live · background · “Docetaxel” · registered Sep 2026
  • NCT07545044 · CSPC Pharmaceutical Group Limited · Phase 2 · live · comparator · “Docetaxel” · registered Apr 2026
  • NCT07518173 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Docetaxel” · registered Apr 2026
  • NCT07441460 · CSPC Pharmaceutical Group Limited · Phase 3 · live · comparator · “Docetaxel” · registered Feb 2026
  • NCT07377643 · Innovent Biologics, Inc. · Phase 3 · live · comparator · “Docetaxel” · registered Jan 2026
Sanofi27% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized1422 studies
pertuzumabRecent, repeated
Evidence
  • NCT07683754 · Daiichi Sankyo · Phase 3 · live · background · “Pertuzumab” · registered Jun 2026
  • NCT07679269 · Novartis · Phase 2 · live · background · “Pertuzumab” · registered Jun 2026
  • NCT07545044 · CSPC Pharmaceutical Group Limited · Phase 2 · live · comparator · “Pertuzumab” · registered Apr 2026
  • NCT07518173 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Pertuzumab” · registered Apr 2026
  • NCT07441460 · CSPC Pharmaceutical Group Limited · Phase 3 · live · comparator · “Pertuzumab” · registered Feb 2026
Hoffmann-La Roche73% of its industry studiesUS: Hoffmann-La Roche (FDA 2012)EU: Hoffmann-La Roche (EMA 2013) + 1 other1322 studies
CarboplatinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07441460 · CSPC Pharmaceutical Group Limited · Phase 3 · live · background · “Carboplatin” · registered Feb 2026
  • NCT07287995 · Astellas Pharma Inc · Phase 2 · live · background · “Carboplatin” · registered Dec 2025
  • NCT07196774 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Carboplatin for Injection” · registered Sep 2025
  • NCT07173751 · BioNTech SE · Phase 3 · live · background · “Carboplatin” · registered Sep 2025
  • NCT07043725 · Sino Biopharmaceutical Limited · Phase 3 · live · comparator · “Trastuzumab injection and Pertuzumab Injection and Docetaxel Injection and Carboplatin Injection” · registered Jun 2025
Eli Lilly and Company16% of its industry studies1318 studies
exemestaneRecent, repeated
Evidence
  • NCT07937605 · Beijing Konruns Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Exemestane” · registered Nov 2026
  • NCT07935317 · Eli Lilly and Company · Phase 2 · live · background · “Exemestane” · registered Nov 2026
  • NCT07349069 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Exemestane tablets” · registered Jan 2026
  • NCT07024173 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Exemestane tablets” · registered Jun 2025
  • NCT06957379 · CSPC Pharmaceutical Group Limited · Phase 2 · live · background · “Exemestane” · registered Apr 2025
Pfizer60% of its industry studiesUS: off-patent, 7 generics marketed1318 studies
eribulinRecent, repeated
Evidence
  • NCT07824869 · Fosun Pharma · Phase 2 · live · background · “Eribulin” · registered Sep 2026
  • NCT07811232 · Advenchen Pharmaceuticals, LLC. · Phase 2 · live · background · “Eribulin” · registered Aug 2026
  • NCT07461454 · MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3 · live · comparator · “Eribulin” · registered Mar 2026
  • NCT07173751 · BioNTech SE · Phase 3 · live · background · “Eribulin” · registered Sep 2025
  • NCT07007559 · ALX Oncology Inc. · Phase 2 · live · background · “Eribulin” · registered May 2025
Eisai Co., Ltd.87% of its industry studiesUS: off-patent, 10 generics marketedEU: off-patent, 2 generics authorized1213 studies
GemcitabineRecent, repeated
Evidence
  • NCT07461454 · MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3 · live · comparator · “Gemcitabine” · registered Mar 2026
  • NCT07173751 · BioNTech SE · Phase 3 · live · background · “Gemcitabine” · registered Sep 2025
  • NCT07007559 · ALX Oncology Inc. · Phase 2 · live · background · “Gemcitabine” · registered May 2025
  • NCT06926868 · Bristol-Myers Squibb · Phase 3 · live · comparator · “Gemcitabine” · registered Apr 2025
  • NCT06435429 · Jazz Pharmaceuticals · Phase 3 · live · background · “Gemcitabine” · registered May 2024
Eli Lilly and Company30% of its industry studiesUS: off-patent, 11 generics marketed1111 studies
LetrozoleRecent, repeated
Evidence
  • NCT07935317 · Eli Lilly and Company · Phase 2 · live · background · “Letrozole” · registered Nov 2026
  • NCT07492641 · BeOne Medicines · Phase 3 · live · background · “Letrozole” · registered Mar 2026
  • NCT07389733 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · live · background · “Letrozole tablets” · registered Jan 2026
  • NCT07349069 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Letrozole tablets” · registered Jan 2026
  • NCT07174336 · Eli Lilly and Company · Phase 3 · live · background · “Letrozole” · registered Sep 2025
Novartis52% of its industry studiesUS: off-patent, 6 generics marketed1023 studies
Albumin-Bound PaclitaxelRecent, repeated
Evidence
  • NCT07738341 · Eddingpharm (Zhuhai) Co., Ltd. · Phase 2 · live · background · “Nab-Paclitaxel” · registered Jul 2026
  • NCT07648914 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Albumin-Bound Paclitaxel” · registered Jun 2026
  • NCT07060807 · Merck & Co., Inc · Phase 3 · live · comparator · “Nab-paclitaxel” · registered Jul 2025
  • NCT07071337 · Sichuan Kelun Pharmaceutical Co.,Ltd. · Phase 3 · live · comparator · “Nab-paclitaxel” · registered Jun 2025
  • NCT06312176 · Merck & Co., Inc · Phase 3 · live · comparator · “Nab-paclitaxel” · registered Mar 2024
Bristol-Myers Squibb43% of its industry studiesEU: Bristol-Myers Squibb (EMA 2008)1012 studies
palbociclibRecent, repeated
Evidence
  • NCT07861932 · KymaThera, Inc. · Phase 2 · live · background · “Palbociclib” · registered Sep 2026
  • NCT07748208 · Hoffmann-La Roche · Phase 2 · live · background · “Palbociclib” · registered Jul 2026
  • NCT07683754 · Daiichi Sankyo · Phase 3 · live · background · “Palbociclib” · registered Jun 2026
  • NCT07492641 · BeOne Medicines · Phase 3 · live · comparator · “Palbociclib” · registered Mar 2026
  • NCT07002177 · forward pharmaceuticals co ltd · Phase 2 · live · background · “Palbociclib 125mg” · registered May 2025
Pfizer81% of its industry studiesUS: Pfizer (FDA 2015)EU: off-patent, 1 generic authorized1012 studies
abemaciclibRecent, repeated
Evidence
  • NCT07492641 · BeOne Medicines · Phase 3 · live · comparator · “Abemaciclib” · registered Mar 2026
  • NCT07100106 · Hoffmann-La Roche · Phase 2 · live · comparator · “Abemaciclib” · registered Jul 2025
  • NCT07002177 · forward pharmaceuticals co ltd · Phase 2 · live · background · “Abemaciclib 150 MG” · registered May 2025
  • NCT06760637 · Pfizer · Phase 3 · live · comparator · “abemaciclib” · registered Dec 2024
  • NCT06380751 · AstraZeneca · Phase 3 · live · background · “Abemaciclib” · registered Mar 2024
Eli Lilly and Company98% of its industry studiesUS: Eli Lilly and Company (FDA 2017)EU: Eli Lilly and Company (EMA 2018)1015 studies
VinorelbineRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07824869 · Fosun Pharma · Phase 2 · live · background · “Vinorelbine” · registered Sep 2026
  • NCT07461454 · MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3 · live · comparator · “Vinorelbine” · registered Mar 2026
  • NCT07007559 · ALX Oncology Inc. · Phase 2 · live · background · “Vinorelbine” · registered May 2025
  • NCT06435429 · Jazz Pharmaceuticals · Phase 3 · live · background · “Vinorelbine” · registered May 2024
  • NCT06202261 · Sino Biopharmaceutical Limited · Phase 2 · live · background · “Vinorelbine tartrate injection” · registered Jan 2024
Eli Lilly and Company9% of its industry studies99 studies
pembrolizumabRecent, repeated
Evidence
  • NCT07287995 · Astellas Pharma Inc · Phase 2 · live · background · “Pembrolizumab” · registered Dec 2025
  • NCT07287917 · Aminex Therapeutics, Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Nov 2025
  • NCT06942234 · Alphamab Oncology · Phase 2 · live · background · “Pembrolizumab” · registered Apr 2025
  • NCT06618287 · Bristol-Myers Squibb · Phase 2 · live · background · “Pembrolizumab” · registered Sep 2024
  • NCT06253871 · Iambic Therapeutics, Inc · Phase 2 · live · background · “Oral treatment with IAM1363 capsules or tablets, administered in combination with pembrolizumab +/- carboplatin +/- pemetrexed” · registered Feb 2024
Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015)911 studies
EverolimusRecent, repeated
Evidence
  • NCT07937605 · Beijing Konruns Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Everolimus (10 mg QD)” · registered Nov 2026
  • NCT07024173 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Everolimus Tablets” · registered Jun 2025
  • NCT07002177 · forward pharmaceuticals co ltd · Phase 2 · live · background · “Everolimus 10 mg” · registered May 2025
  • NCT06680921 · Simcere Pharmaceutical Group Limited · Phase 3 · live · background · “Everolimus (Afinitor®)” · registered Nov 2024
  • NCT06428396 · Merck & Co., Inc · Phase 2 · live · comparator · “Everolimus” · registered May 2024
Novartis92% of its industry studiesUS: off-patent, 14 generics marketedEU: Novartis (EMA 2009)99 studies
ribociclibRecent, repeated
Evidence
  • NCT07647328 · AstraZeneca · Phase 3 · live · background · “Ribociclib” · registered May 2026
  • NCT07492641 · BeOne Medicines · Phase 3 · live · comparator · “Ribociclib” · registered Mar 2026
  • NCT07405801 · Hoffmann-La Roche · Phase 2 · live · background · “Ribociclib” · registered Feb 2026
  • NCT07174336 · Eli Lilly and Company · Phase 3 · live · background · “Ribociclib” · registered Sep 2025
  • NCT07054190 · Hoffmann-La Roche · Phase 2 · live · background · “Ribociclib” · registered Jun 2025
Novartis87% of its industry studiesUS: Novartis (FDA 2017)EU: Novartis (EMA 2017)915 studies
Ado-Trastuzumab EmtansineRecent, repeated
Evidence
  • NCT07673029 · GeneQuantum Healthcare (Suzhou) Co., Ltd. · Phase 3 · live · comparator · “T-DM1” · registered Jun 2026
  • NCT07008976 · Sino Biopharmaceutical Limited · Phase 3 · live · comparator · “Trastuzumab Emtansine for Injection” · registered May 2025
  • NCT06968585 · Sichuan Kelun Pharmaceutical Co.,Ltd. · Phase 3 · live · comparator · “T-DM1” · registered Apr 2025
  • NCT06830889 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “T-DM1” · registered Feb 2025
  • NCT06846437 · CSPC Pharmaceutical Group Limited · Phase 3 · live · comparator · “Trastuzumab emtansine (T-DM1)” · registered Jan 2025
Hoffmann-La Roche100% of its industry studiesUS: Hoffmann-La Roche (FDA 2013)EU: Hoffmann-La Roche (EMA 2013)810 studies
AnastrozoleRecent, repeated
Evidence
  • NCT07935317 · Eli Lilly and Company · Phase 2 · live · background · “Anastrozole” · registered Nov 2026
  • NCT07349069 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Anastrozole Tablets” · registered Jan 2026
  • NCT07174336 · Eli Lilly and Company · Phase 3 · live · background · “Anastrozole” · registered Sep 2025
  • NCT07024173 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Anastrozole Tablets” · registered Jun 2025
  • NCT06957379 · CSPC Pharmaceutical Group Limited · Phase 2 · live · background · “Anastrozole” · registered Apr 2025
AstraZeneca66% of its industry studiesUS: off-patent, 6 generics marketed812 studies
CyclophosphamideRecent, repeated
Evidence
  • NCT07441460 · CSPC Pharmaceutical Group Limited · Phase 3 · live · background · “Cyclophosphamide” · registered Feb 2026
  • NCT06966700 · Merck & Co., Inc · Phase 3 · live · comparator · “Cyclophosphamide” · registered May 2025
  • NCT06829199 · Merck & Co., Inc · Phase 2 · background · “Cyclophosphamide” · registered Feb 2025
  • NCT06797635 · Merck & Co., Inc · Phase 2 · live · comparator · “Cyclophosphamide” · registered Jan 2025
  • NCT06389006 · RemeGen Co., Ltd. · Phase 2 · live · background · “Cyclophosphamide” · registered Apr 2024
Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed79 studies
TamoxifenRecent, repeated
Evidence
  • NCT07349069 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Tamoxifen Citrate Tablets” · registered Jan 2026
  • NCT07287098 · Eli Lilly and Company · Phase 2 · live · comparator · “Tamoxifen 20 mg” · registered Dec 2025
  • NCT06449027 · Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Leuprorelin Acetate Microspheres for Injection” · registered May 2024
  • NCT05768139 · Eli Lilly and Company · Phase 2 · live · background · “Tamoxifen” · registered Mar 2023
  • NCT05645536 · Tolmar Inc. · Phase 3 · live · background · “Tamoxifen” · registered Dec 2022
AstraZeneca38% of its industry studiesUS: off-patent, 4 generics marketed68 studies
trastuzumab deruxtecanRecent, repeated
Evidence
  • NCT07678957 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 · live · comparator · “DS-8201” · registered Jun 2026
  • NCT07497386 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · live · comparator · “Trastuzumab Deruxtecan for Injection” · registered Mar 2026
  • NCT07294508 · Fosun Pharma · Phase 3 · live · background · “T-Dxd + Pertuzumab” · registered Dec 2025
  • NCT06832202 · Fosun Pharma · Phase 2 · live · background · “Trastuzumab Deruxtecan” · registered Feb 2025
  • NCT06324357 · Boehringer Ingelheim · Phase 2 · live · background · “Trastuzumab deruxtecan” · registered Mar 2024
Daiichi Sankyo53% of its industry studiesUS: Daiichi Sankyo (FDA 2019)EU: Daiichi Sankyo (EMA 2021)67 studies
EpirubicinRecent, repeated
Evidence
  • NCT07441460 · CSPC Pharmaceutical Group Limited · Phase 3 · live · background · “Epirubicin” · registered Feb 2026
  • NCT06966700 · Merck & Co., Inc · Phase 3 · live · comparator · “Epirubicin” · registered May 2025
  • NCT06829199 · Merck & Co., Inc · Phase 2 · background · “Epirubicin Hydrochloride” · registered Feb 2025
  • NCT06797635 · Merck & Co., Inc · Phase 2 · live · comparator · “Epirubicin hydrochloride” · registered Jan 2025
  • NCT06389006 · RemeGen Co., Ltd. · Phase 2 · live · background · “Epirubicin” · registered Apr 2024
GlaxoSmithKline33% of its industry studiesUS: Pfizer (FDA 1999)47 studies
DoxorubicinRecent, repeated
Evidence
  • NCT07441460 · CSPC Pharmaceutical Group Limited · Phase 3 · live · background · “Doxorubicin” · registered Feb 2026
  • NCT06966700 · Merck & Co., Inc · Phase 3 · live · comparator · “Doxorubicin” · registered May 2025
  • NCT06829199 · Merck & Co., Inc · Phase 2 · background · “Doxorubicin (hydrochloride)” · registered Feb 2025
  • NCT06797635 · Merck & Co., Inc · Phase 2 · live · comparator · “Doxorubicin hydrochloride” · registered Jan 2025
  • NCT06112379 · AstraZeneca · Phase 3 · live · comparator · “Doxorubicin” · registered Oct 2023
Hoffmann-La Roche10% of its industry studiesUS: off-patent, 14 generics marketed46 studies
GoserelinRecent, repeated
Evidence
  • NCT07287098 · Eli Lilly and Company · Phase 2 · live · background · “Goserelin” · registered Dec 2025
  • NCT05827081 · Novartis · Phase 3 · live · background · “Goserelin” · registered Apr 2023
  • NCT05607004 · Atossa Therapeutics, Inc. · Phase 2 · live · background · “goserelin” · registered Oct 2022
  • NCT05161195 · Novartis · Phase 4 · live · background · “Goserelin” · registered Dec 2021
  • NCT05110170 · Luye Pharma Group Ltd. · Phase 3 · comparator · “ZOLADEX® 3.6 mg” · registered Nov 2021
AstraZeneca57% of its industry studiesUS: TerSera Therapeutics LLC (FDA 1989)34 studies
AlpelisibRecent, repeated
Evidence
  • NCT05646862 · Hoffmann-La Roche · Phase 3 · live · comparator · “Alpelisib” · registered Dec 2022
  • NCT05563220 · Menarini Group · Phase 2 · live · background · “Alpelisib” · registered Sep 2022
  • NCT05501886 · Celcuity Inc · Phase 3 · live · comparator · “Alpelisib” · registered Aug 2022
  • NCT03284957 · Sanofi · Phase 2 · background · “Alpelisib” · registered Sep 2017
Novartis89% of its industry studiesUS: Novartis (FDA 2019)EU: Novartis (EMA 2020)33 studies
sacituzumab govitecanRecent, repeated
Evidence
  • NCT07461454 · MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3 · live · comparator · “Sacituzumab govitecan” · registered Mar 2026
  • NCT06827613 · Marengo Therapeutics, Inc. · Phase 2 · live · background · “Sacituzumab Govitecan (SG)” · registered Jan 2025
  • NCT05867251 · Avenzo Therapeutics, Inc. · Phase 2 · live · background · “Sacituzumab Govitecan-hziy” · registered Apr 2023
  • NCT04143711 · Dragonfly Therapeutics · Phase 2 · background · “Sacituzumab Govitecan-hziy” · registered Oct 2019
Gilead Sciences77% of its industry studiesUS: IMMUNOMEDICS INC (FDA 2020)EU: Gilead Sciences (EMA 2021)33 studies
capivasertibRecent, repeated
Evidence
  • NCT07287917 · Aminex Therapeutics, Inc. · Phase 2 · live · background · “Capivasertib” · registered Nov 2025
  • NCT06982521 · Relay Therapeutics, Inc. · Phase 3 · live · comparator · “Capivasertib” · registered May 2025
  • NCT05563220 · Menarini Group · Phase 2 · live · background · “Capivasertib” · registered Sep 2022
AstraZeneca100% of its industry studiesUS: AstraZeneca (FDA 2023)EU: AstraZeneca (EMA 2024)33 studies
olaparibRecent, repeated
Evidence
  • NCT06966700 · Merck & Co., Inc · Phase 3 · live · background · “Olaparib” · registered May 2025
  • NCT06829199 · Merck & Co., Inc · Phase 2 · background · “Olaparib (if approved/available locally)” · registered Feb 2025
  • NCT06797635 · Merck & Co., Inc · Phase 2 · live · background · “Olaparib” · registered Jan 2025
  • NCT06065059 · Tango Therapeutics, Inc. · Phase 2 · background · “Olaparib” · registered Sep 2023
  • NCT05700669 · Valerio Therapeutics · Phase 2 · background · “Olaparib” · registered Dec 2022
AstraZeneca76% of its industry studiesUS: AstraZeneca (FDA 2017)EU: AstraZeneca (EMA 2014)35 studies
BevacizumabRecent, repeated
Evidence
  • NCT06271837 · AstraZeneca · Phase 2 · live · background · “Bevacizumab” · registered Jan 2024
  • NCT05579366 · Genmab · Phase 2 · live · background · “Bevacizumab” · registered Oct 2022
  • NCT03961698 · Infinity Pharmaceuticals, Inc. · Phase 2 · live · background · “Bevacizumab” · registered Apr 2019
  • NCT02734004 · AstraZeneca · Phase 2 · live · background · “Bevacizumab” · registered Mar 2016
  • NCT00868634 · iOMEDICO AG · Phase 3 · background · “bevacizumab” · registered Mar 2009
Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others22 studies
tucatinibRecent, repeated
Evidence
  • NCT07413939 · Hoffmann-La Roche · Phase 3 · live · comparator · “Tucatinib” · registered Feb 2026
  • NCT06686394 · Merck & Co., Inc · Phase 2 · live · background · “Tucatinib” · registered Nov 2024
  • NCT05091528 · Silverback Therapeutics · Phase 2 · background · “tucatinib” · registered Oct 2021
Pfizer84% of its industry studiesUS: Pfizer (FDA 2020)EU: Pfizer (EMA 2021)22 studies
osimertinibRecent, repeated
Evidence
  • NCT06618287 · Bristol-Myers Squibb · Phase 2 · live · background · “Osimertinib” · registered Sep 2024
  • NCT05785741 · DualityBio Inc. · Phase 2 · live · background · “Osimertinib” · registered Mar 2023
AstraZeneca93% of its industry studiesUS: AstraZeneca (FDA 2015)EU: AstraZeneca (EMA 2016)22 studies
elacestrantRecent, repeated
Evidence
  • NCT06938711 · Context Therapeutics Inc. · Phase 2 · background · “Elacestrant” · registered May 2023
  • NCT05618613 · Context Therapeutics Inc. · Phase 2 · background · “Elacestrant” · registered Nov 2022
  • NCT05573126 · Ellipses Pharma · Phase 2 · live · background · “Elacestrant” · registered Oct 2022
Menarini Group75% of its industry studiesUS: Menarini Group (FDA 2023)EU: Menarini Group (EMA 2023)23 studies

61 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
trastuzumab botidotin☆ Track1 live phase-3 study: NCT06968585Sichuan Kelun Pharmaceutical Co.,Ltd.
taragarestrant☆ Track1 live phase-3 study: NCT06954961InventisBio Co., Ltd
culmerciclib☆ Track2 live phase-3 studies: NCT05780567, NCT05365178Sino Biopharmaceutical Limited
DocetaxelApproved: US · EU☆ Track4 live phase-3 studies: NCT07805135, NCT06747338, NCT07441460CSPC Pharmaceutical Group Limited
anbenitamab☆ Track3 live phase-3 studies: NCT06747338, NCT07441460, NCT05838066CSPC Pharmaceutical Group Limited

The 5 in phase 3 with the nearest primary completion, of 191 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (64)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Nov 2026 est.elacestrant · Menarini Group · Phase 2 main aimNCT05596409 ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study — primary endpoint: Progression-free survival (PFS) · 61 enrolled
  • Nov 2026 est.beruzatatug pelitecan · MediLink Therapeutics (Suzhou) Co., Ltd. · Phase 2 main aimNCT06107686 A Study of YL202 in Selected Patients With Advanced Solid Tumors — primary endpoint: ORR assessed according to RECIST v1.1 · 200 enrolled
  • 30 Nov 2026 est.trastuzumab botidotin · Sichuan Kelun Pharmaceutical Co.,Ltd. · Phase 3 main aimvs Ado-Trastuzumab EmtansineNCT06968585 A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy — primary endpoint: Progression-free survival (PFS) · 365 enrolled

61 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Breast Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 83 open · Tyrosine kinase inhibitors (TKIs) 75 open · Antibody-drug conjugates (ADCs) 70 open · Antimitotic agents 52 open · Aromatase inhibitors 43 open

Coming up

1,252studies finish main data collection within a year71 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 2,398 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 590 (25%) stop at 75 or younger. 103 (4%) take children under 18. 1,269 (53%) are for women only and 3 (<1%) for men only; 213 (9%) take healthy volunteers.

Recruiting studies that take each age, of 2,398
AgeWomenMen
1095 (4%)46 (2%)
182,066 (86%)1,052 (44%)
302,235 (93%)1,095 (46%)
402,288 (95%)1,104 (46%)
502,317 (97%)1,109 (46%)
652,311 (96%)1,109 (46%)
752,065 (86%)1,077 (45%)
851,711 (71%)974 (41%)

Across all 14,840 studies, recruiting or not: 23% stop at 75 or younger and 7% at 65; 6% take children; 63% are for women only and <1% for men only; 10% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Breast Neoplasms studies take

Of 1,303 phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 51 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 144 mo25–65 · 762 studies39 mo22–56 · 389 studies48 mo28–77 · 373 studies
Phase 1/262 mo45–88 · 330 studies59 mo44–75 · 163 studies67 mo45–95 · 167 studies
Phase 251 mo30–82 · 1,303 studies34 mo22–53 · 232 studies56 mo34–89 · 1,071 studies
Phase 2/357 mo32–88 · 56 studies—57 mo31–91 · 43 studies
Phase 359 mo36–96 · 600 studies40 mo28–63 · 272 studies79 mo50–127 · 328 studies
Phase 442 mo20–64 · 130 studies—46 mo20–64 · 110 studies
Interventional, no phase33 mo15–66 · 2,776 studies24 mo10–59 · 110 studies33 mo16–66 · 2,666 studies
Observational55 mo25–125 · 1,381 studies43 mo26–70 · 189 studies58 mo25–138 · 1,192 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Started recruiting27

Show 22 more

Newly registered87

Show 45 more

and 37 more not listed

Studies

Recruiting first, then most recently updated. Showing 50 of 14,840. Browse all 14,840 → or search them.